• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NLS Pharmaceutics AG

NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
June 10, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
June 06, 2022
From NLS Pharmaceutics AG
Via AccessWire
Topics Bankruptcy Initial Public Offering
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
June 02, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
May 04, 2022
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
April 26, 2022
From NLS Pharmaceutics AG
Via AccessWire
Topics Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 13, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
April 01, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
March 31, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
March 28, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
March 25, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
March 16, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
February 25, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
February 11, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
February 07, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
January 12, 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
January 04, 2022
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
November 30, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics CEO Issues Letter to Shareholders
November 01, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Initial Public Offering Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
October 14, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Product Recall Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
September 30, 2021
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
September 28, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
September 24, 2021
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
September 14, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
September 08, 2021
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
August 19, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
July 19, 2021
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap